Kannalife, Inc. is a biopharmaceutical company leading innovation in research, development, and discovery of natural and novel biomimetic cannabinoid therapeutic agents. The Company is focused on the development of proprietary cannabidiol (CBD) and CBD-like molecules for patients suffering from unmet medical needs of neurodegenerative disorders - including chemotherapy-induced peripheral neuropathy (CIPN), a chronic neuropathy caused by toxic chemotherapeutic agents; hepatic encephalopathy (HE), a neurotoxic brain-liver disorder caused by excessive concentrations of ammonia and ethanol in the brain; mild traumatic brain injury (mTBI), a disorder associated with single and repetitive impact injuries; and chronic traumatic encephalopathy (CTE) a disease associated with highly repetitive impact injuries in professional and amateur sports.

The Company's family of proprietary molecules focuses on treating oxidative stress-related and neurodegenerative diseases. Kannalife conducts its research and development efforts at the Pennsylvania Biotechnology Center of Bucks County in Doylestown, PA.

**CORPORATE PROFILE**

Kannalife is a pioneer in the emerging Cannabinoid Therapeutics market to reach $20B by 2020*

---

**STOCK PERFORMANCE**

<table>
<thead>
<tr>
<th>Symbol</th>
<th>KLFE</th>
</tr>
</thead>
<tbody>
<tr>
<td>Exchange</td>
<td>OTCQB</td>
</tr>
<tr>
<td>Market Cap.</td>
<td>81.65m</td>
</tr>
<tr>
<td>52 Week Range</td>
<td>0.342 - 6.90</td>
</tr>
<tr>
<td>Close</td>
<td>1.00</td>
</tr>
<tr>
<td>Volume</td>
<td>193</td>
</tr>
<tr>
<td>Shares Outstanding</td>
<td>74,225,141</td>
</tr>
<tr>
<td>As of Jun 12, 2020 9:30 am</td>
<td></td>
</tr>
</tbody>
</table>

---

**MANAGEMENT TEAM**

Dean Petkanas – Chairman & CEO
William A. Kinney, PhD – Chief Scientific Officer
Thoma Kikis – Chief Communications Officer, Board Director
Mark Corrao – Chief Financial Officer

**BOARD OF DIRECTORS**

Dean Petkanas – Chairman & CEO
Blake Schroeder – Board Director
Thoma Kikis – Founder / Chief Communications Officer, Board Director
Robert Malasek – Board Director
Timothy Scott, PhD – Board Director

**RECENT HEADLINES**

- **Jun 4, 2020** - Medical Marijuana, Inc. Investment Company Kannalife, Inc. Appoints Terrence O. Tormey to Board of Advisors
- **Jun 2, 2020** - Kannalife, Inc. Appoints Terrence O. Tormey to the Company's Board of Advisors
- **Apr 16, 2020** - Kannalife, Inc. CEO Featured in OTCQB Podcast Discussing KLS-13019 and Its Potential Role as a Non-Opioid Treatment for Neuropathic Pain
- **Apr 14, 2020** - Kannalife, Inc. Announces Results from Comparative UVB-Radiation Study on Atopidine(TM) Versus CBD

**INVESTMENT HIGHLIGHTS**

We have made significant improvements in the chemistry, efficacy, and safety of CBD-like molecules. KLS-13019 is up to 200X more potent, 10X more bioavailable, 5X safer and 1000 times more effective than CBD.

- Received US Patent 9,611,213 (April 2017) “Novel Functionalized 1,3 Benzene Diols and Their Method of Use for the Treatment of Hepatic Encephalopathy”
- Received NIH/NIDA Grant #1R41DA044898 (December 2017) on the Development of KLS-13019 for Chemotherapy Induced Peripheral Neuropathy (CIPN) and drug dependence
- Received US Patent 10,004,722 (June 2018) “Method for Treating Hepatic Encephalopathy or a Disease Associated with Free Radical Mediate Stress and Oxidative Stress with Novel Functionalized 1,3- Benzene Diols”
- Article Published in The Journal of Neuroscience [Springer] (August 2018) “Pharmacology Comparisons Between Cannabidiol and KLS-13019”

---

**GROWTH STRATEGY**

Kannalife is a pioneer in the emerging Cannabinoid Therapeutics market to reach $20B by 2020*